IntegraMed Investor Says $170M Sagard Buyout Price Too Low

Law360, New York (June 26, 2012, 6:31 PM EDT) -- An IntegraMed America Inc. shareholder on Tuesday hit the company and its prospective buyer Sagard Capital Partners LP with a proposed class action seeking to block the pair's planned merger, which he says comes with a lowballed $169.5 million price tag.

The deal would take the the manager of outpatient specialty care facilities private, depriving shareholders of any benefits from the positive trajectory IntegraMed's shares would likely continue to follow, investor Charles Francis contends, calling the $14.05 per-share purchase offer unfair and grossly inadequate.

The per-share...
To view the full article, register now.